文献速递慢性肾脏病血液净化与透析

血管生成素2与VEGF-A浓度和临床终点的关联

Associations of Angiopoietin 2 and Vascular Endothelial Growth Factor-A Concentrations with Clinical End Points.
PubMed 文献 · Clin J Am Soc Nephrol · 2023-12-14

基线血管生成素2每增加50%与主要复合终点风险升高相关(HR 1.27,95%CI 1.13-1.43),VEGF-A与结局无关。

要点

  • 基线血管生成素2最高四分位者临床风险最高
  • 卡格列净显著降低血管生成素2但不降低VEGF-A
  • 血管生成素2与主要复合终点风险独立于VEGF-A相关

核心结论

  • 在糖尿病肾病人群中,较高血管生成素2水平与心肾风险相关且独立于VEGF-A,卡格列净可降低血管生成素2浓度。

主要发现

  • 基线血管生成素2最高四分位者临床风险最高,而VEGF-A最高四分位者无此表现。
  • 卡格列净显著降低血管生成素2浓度(校正几何均值比0.94,95%CI 0.92-0.95,P<0.001),但不降低VEGF-A。
  • 基线对数血管生成素2每增加50%与主要复合终点风险升高相关(HR 1.27,95%CI 1.13-1.43)。
  • 第1年血管生成素2较基线变化解释了卡格列净对主要复合终点效应的10%。
  • VEGF-A浓度单独或与血管生成素2联合均与结局无关。

临床怎么用

  • 血管生成素2可作为糖尿病肾病患者心肾风险的潜在生物标志物,卡格列净治疗可降低其水平。

局限性

  • 研究为CREDENCE试验的事后分析,血管生成素2变化仅解释卡格列净效应的10%,因果关系需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Angiopoietin 2 regulates endothelial function partially mediated by vascular endothelial growth factor-A (VEGF-A) and may play a role in diabetic kidney disease (DKD). We assessed the association of angiopoietin 2 and VEGF-A with cardiorenal outcomes and investigated the effect of canagliflozin on angiopoietin 2 and VEGF-A concentrations. METHODS: Two thousand five hundred sixty-five study participants with DKD and available plasma samples treated with canagliflozin or placebo in the Canagliflozin and Kidney Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial were included. Angiopoietin 2 and VEGF-A concentrations were measured at baseline, year 1, and year 3. The primary composite end point of the trial was a composite of kidney failure, doubling of the serum creatinine level, and kidney or cardiovascular death. RESULTS: Patients with the highest baseline quartile of angiopoietin 2, but not VEGF-A, concentration had the highest risk clinical profile. Treatment with canagliflozin significantly lowered concentrations of angiopoietin 2 (adjusted geometric mean ratio: 0.94; 95% confidence interval, 0.92 to 0.95; P < 0.001), but not VEGF-A. In multivariable-adjusted modeling, each 50% increment in log baseline angiopoietin 2 concentrations was associated with a higher risk of primary composite outcome (hazard ratio, 1.27; 95% confidence interval, 1.13 to 1.43). Angiopoietin 2 change at year 1 compared with baseline explained 10% of the effect of canagliflozin on the primary composite outcome. VEGF-A concentrations were not associated with outcomes, alone or in combination with angiopoietin 2. CONCLUSIONS: Higher angiopoietin 2 levels were associated with cardiorenal risk among individuals with DKD independent of VEGF-A. Canagliflozin lowered angiopoietin 2 concentrations. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy, NCT02065791 .

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Mohebi R, Liu Y, Hansen MK, et al. Associations of Angiopoietin 2 and Vascular Endothelial Growth Factor-A Concentrations with Clinical End Points. Clin J Am Soc Nephrol. 2023. PMID: 38099944. doi:10.2215/CJN.0000000000000389

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。